Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,803 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Sensitivity Clear all
Completed Phase 2 Interventional

Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma)

NCT06940141
View directory record Official record
Conditions
Asthma Acute
Interventions
Rademikibart in prefilled syringe, Matching placebo in prefilled syringe
Combination Product · Drug
Lead sponsor
Connect Biopharm LLC
Industry
Eligibility
12 Years to 75 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
21
States / cities
Palo Alto, California • Valencia, California • Wilmington, Delaware + 17 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 24, 2026, 10:26 PM EDT
Not listed No phase listed Observational

Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis

NCT03145922
View directory record Official record
Conditions
Sarcoidosis, Sarcoidosis, Pulmonary
Interventions
Observational Study
Other
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Oct 24, 2026, 10:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Impact of FeNO Measured With the NIOX MINO® Device in Identifying Asthma Among Patients With Prolonged Respiratory Symptoms

NCT01518322
View directory record Official record
Conditions
Asthma
Interventions
NIOX MINO®
Device
Lead sponsor
Aerocrine AB
Industry
Eligibility
7 Years to 65 Years
Enrollment
235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
13
States / cities
Byron, Minnesota • Chatfield, Minnesota • Pine Island, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Not applicable Interventional

Video vs. TTG Respiratory Inhaler Technique Assessment and InstructioN (V-TRaIN)

NCT02611531
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Video Module Education (VME), Teach-To-Goal (TTG)
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 24, 2026, 10:26 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Elucidation of Acid-Induced Pulmonary Inflammation

NCT00361972
View directory record Official record
Conditions
Gastroesophageal Reflux, Asthma
Interventions
lansoprazole, placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid

NCT00845195
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Olopatadine HCl Nasal Spray, 0.6%, Azelastine HCl Nasal Spray, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2010 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers

NCT00223951
View directory record Official record
Conditions
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Interventions
R89674 (generic name not yet established)
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
3 Years and older
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
Phoenix, Arizona • Bel Air, Maryland • North Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Ampyra for Optic Neuritis in Multiple Sclerosis

NCT01337986
View directory record Official record
Conditions
Multiple Sclerosis, Optic Neuritis
Interventions
Dalfampridine/Placebo, Placebo/Dalfampridine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Oct 24, 2026, 10:26 PM EDT
Completed No phase listed Observational

Connect Lung Outcomes With Bronchodilator Use

NCT04417842
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Asthma
Interventions
Respimetrix flow-volume monitoring device
Diagnostic Test
Lead sponsor
Pulmonary Critical Care Associates of Baltimore
Other
Eligibility
18 Years and older
Enrollment
30 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 24, 2026, 10:26 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heart Disease Risk Factors in Major Depression

NCT00001969
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies

NCT02038894
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Intubated with Sevoflurane (IS), Intubated with Propofol (IP), Zofran - no intubation, Propofol
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 12 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 24, 2026, 10:26 PM EDT
Recruiting Phase 2 Interventional

Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer

NCT05915442
View directory record Official record
Conditions
Oligometastatic Prostate Cancer
Interventions
Quemliclustat, Etrumadenant, Zimberelimab, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
Catherine Spina
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Phase 2 Interventional

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

NCT01639846
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
RX-10045, Vehicle for RX-10045 arm
Drug
Lead sponsor
C.T. Development America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 8, 2013 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Phase 3 Interventional Results available

A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA

NCT02258542
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 75 Years
Enrollment
2,133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
100
States / cities
Andalusia, Alabama • Birmingham, Alabama • Scottsboro, Alabama + 80 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Phase 2 Interventional

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

NCT00000891
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Saquinavir, Delavirdine mesylate, Lamivudine, Stavudine, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
16 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
3
States / cities
Denver, Colorado • Chicago, Illinois • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Phase 4 Interventional

Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen

NCT00638118
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Fexofenadine
Drug
Lead sponsor
Sanofi
Industry
Eligibility
15 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 24, 2026, 10:26 PM EDT
Not listed Not applicable Interventional

Acceptability/Feasibility Testing of SCAR

NCT04859790
View directory record Official record
Conditions
Social Anxiety
Interventions
Social Concerns Appraisal Retraining
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 9, 2021 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Phase 4 Interventional

The Effect of Xolair (Omalizumab) on Allergy Blood Cells

NCT00657891
View directory record Official record
Conditions
Asthma
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Creighton University
Other
Eligibility
16 Years to 50 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 1, 2013 · Synced Oct 24, 2026, 10:26 PM EDT
Terminated Phase 2 Interventional

Study of XL999 in Patients With Previously Treated Ovarian Cancer

NCT00277290
View directory record Official record
Conditions
Ovarian Cancer
Interventions
XL999
Drug
Lead sponsor
Symphony Evolution, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
9
States / cities
Greenbrae, California • Port Saint Lucie, Florida • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2010 · Synced Oct 24, 2026, 10:26 PM EDT
Terminated Phase 3 Interventional Results available

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

NCT02246920
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
Fluticasone propionate, Flonase®, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
12 Years and older
Enrollment
1,474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Introduction and Maintenance of Still Eating Protein Blends in Support of Infant Nutritional Goals

NCT03667118
View directory record Official record
Conditions
Food Allergy
Interventions
Food Supplement
Dietary Supplement
Lead sponsor
Northwestern University
Other
Eligibility
5 Months to 11 Months
Enrollment
705 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 24, 2026, 10:26 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema

NCT01036659
View directory record Official record
Conditions
Angioedema
Interventions
ecallantide - Kallikrein inhibitor that blocks the production of bradykinin
Drug
Lead sponsor
Bernstein, Jonathan A., M.D.
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
3
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 24, 2026, 10:26 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

NCT02489318
View directory record Official record
Conditions
Prostate Cancer
Interventions
Apalutamide, Placebo, Androgen Deprivation Therapy (ADT)
Drug
Lead sponsor
Aragon Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,052 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
39
States / cities
Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 10:26 PM EDT
Completed Phase 3 Interventional

A Study of GW685698X for the Treatment Of Perennial Allergic Rhinitis in Adolescents and Adults

NCT00116818
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
GW685698X aqueous nasal spray
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Oct 24, 2026, 10:26 PM EDT